Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 153 Melanoma 133 Lymphoma 124 Prostatic Neoplasms 123 Carcinoma, Non-Small-Cell Lung 113 Multiple Myeloma 106 Carcinoma, Renal Cell 92 Ovarian Neoplasms 88 Leukemia, Myeloid, Acute 83 Sarcoma 82 Lung Neoplasms 80 Leukemia, Lymphocytic, Chronic, B-Cell 80 Leukemia 79 Colorectal Neoplasms 79 Colonic Neoplasms 74 Rectal Neoplasms 71 Lymphoma, Non-Hodgkin 69 Pancreatic Neoplasms 68 Carcinoma, Ovarian Epithelial 66 Neoplasms 65 Lymphoma, Large B-Cell, Diffuse 65 Brain Neoplasms 65 Precursor Cell Lymphoblastic Leukemia-Lymphoma 64 Lymphoma, Follicular 58 Kidney Neoplasms 58 Glioblastoma 57 Fallopian Tube Neoplasms 54 Carcinoma, Hepatocellular 51 Lymphoma, Mantle-Cell 50 Central Nervous System Neoplasms 50

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NIH × Lupus Nephritis × Clear all

NCT00447265 2013-02-12

Etanercept for the Treatment of Lupus Nephritis

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Terminated

1 enrolled 15 charts

Lupus Nephritis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡